The Orphan Drug Designation (ODD) is a status assigned by EMA to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.
We have summarized the work process for you to have always at hand.
Have a look at the complete process:
For further information, queries or assistance, contact us at: info@asphalion.com
Search News & Events
Share
La formación y conocimiento del Sistema de Autorregulación de Farmaindustria forma parte del compromiso que las compañías farmacéuticas y las personas que trabajan en ellas deben tener presente en su toma de decisiones.
Outsource your publishing solutions any time and maximize your time and resources
Watch Asphalion experts Ivette Camarasa and Nuria García Pazos in this webinar talking about EMA Policy 0070 and sharing key recommendations for a successful publication.
Services
Memberships & Partnerships
Quality Management System
© Asphalion
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
